Subsai Kongsengdao1, Saksit Kritalukkul. 1. Division of Neurology, Department of Medicine, Rajvithi Hospital, Public Health Ministry, Bangkok, Thailand. Skhongsa@gmail.com
Abstract
BACKGROUND:Hemifacial spasm (HFS) is a common movement disorder presented with unilateral, intermittent, irregular tonic or clonic contraction of facial expression muscles without any identifiable etiology. Comparison of quality of life (QoL) between Dysport and Neuronox has not been studied in HFS patients. OBJECTIVE: To evaluate the QoL after treatment with botulinum toxin A (Dysport and Neuronox) injection in HFS patient. MATERIAL AND METHOD: A 24-week, double-blind, randomized, cross-over comparison of QoL in HFS patients after being treated withbotulinum toxin A (Dysport) and botulinum toxin A (Neuronox) was performed. Assessment of QoL composed of hemifacial spasm-30 (HFS-30), medical outcome study short form 36 items (SF-36), abnormal involuntary movement scale (AIMS) and center for epidemiologic studies-depression (CES-D) questionnaire, were performed at week 0, week 12, and week 24. The 24-hour HFS diary, recorded for 4 weeks after treatment was also evaluated. RESULTS:Total of 26 HFS patients were enrolled between May 2010 and January 2011. The mean HFS-30, AIMS and CES-D were reduced after treatment without any difference between the two groups. The mean SF-36 was not changed in both groups. However mean HFS-30 (p = 0.09), AIMS (p = 0.02) and CES-D (p < 0.001) of all treated patients were reduced across the treatment period. Total intensity score of HFS, duration of facial muscles spasm per day and duration of functional impairment per day in Dysport group were significantly lower than the Neuronox group (p < 0.001). CONCLUSION: There was no difference between Dysport and Neuronox in the aspect of QoL in HFS patients. However, there was improvement of QoL after multiple botulinum toxin A injection.
RCT Entities:
BACKGROUND:Hemifacial spasm (HFS) is a common movement disorder presented with unilateral, intermittent, irregular tonic or clonic contraction of facial expression muscles without any identifiable etiology. Comparison of quality of life (QoL) between Dysport and Neuronox has not been studied in HFSpatients. OBJECTIVE: To evaluate the QoL after treatment with botulinum toxin A (Dysport and Neuronox) injection in HFSpatient. MATERIAL AND METHOD: A 24-week, double-blind, randomized, cross-over comparison of QoL in HFSpatients after being treated with botulinum toxin A (Dysport) and botulinum toxin A (Neuronox) was performed. Assessment of QoL composed of hemifacial spasm-30 (HFS-30), medical outcome study short form 36 items (SF-36), abnormal involuntary movement scale (AIMS) and center for epidemiologic studies-depression (CES-D) questionnaire, were performed at week 0, week 12, and week 24. The 24-hour HFS diary, recorded for 4 weeks after treatment was also evaluated. RESULTS: Total of 26 HFSpatients were enrolled between May 2010 and January 2011. The mean HFS-30, AIMS and CES-D were reduced after treatment without any difference between the two groups. The mean SF-36 was not changed in both groups. However mean HFS-30 (p = 0.09), AIMS (p = 0.02) and CES-D (p < 0.001) of all treated patients were reduced across the treatment period. Total intensity score of HFS, duration of facial muscles spasm per day and duration of functional impairment per day in Dysport group were significantly lower than the Neuronox group (p < 0.001). CONCLUSION: There was no difference between Dysport and Neuronox in the aspect of QoL in HFSpatients. However, there was improvement of QoL after multiple botulinum toxin A injection.